Malignant Peritoneal Mesothelioma: A Rare Cause of Ascites

Abdisamad M. Ibrahim, MD\(^1\), Mohammad Al-Akchar, MD\(^1\), Zainab Obaidi, MD\(^2\), and Hamid Al-Johany, MD\(^1\)

Abstract
Malignant peritoneal mesothelioma (MPM) is a rare diagnosis that presents with difficulties in diagnosis and management. This article reports a case of an 88-year-old male who presented with a 2-week history of abdominal distention and bloating. He worked at an insulation production factory between the ages of 23 and 25 years with presumed asbestos exposure. On the computed tomography scan of the abdomen/pelvis, the patient was found to have diffuse omental, peritoneal, and mesenteric nodularity with moderate to large ascites. Omental biopsy revealed MPM. The overall prognosis of MPM remains poor, with a median survival time of 12 months at the time of diagnosis. Treatment modalities offered in the United States include chemotherapy alone, cytoreductive surgery alone, or cytoreductive surgery/chemotherapy combination.

Keywords
peritoneal mesothelioma, mesothelioma, asbestos exposure

Introduction
Malignant peritoneal mesothelioma (MPM) is a rare and aggressive disease that arises from the lining mesothelial cells of the peritoneum. The incidence of MPM is one in a million, and in the United States, it accounts for 10\% to 15\% of all cases of mesothelioma.\(^1\,\,2\) There is a strong link between asbestos exposure and development of MPM, with approximately 50\% of reported cases having asbestos exposure. The latency period between asbestos exposure and development of mesothelioma is approximately 40 to 45 years; thus, diagnosis can be challenging at the time of presentation.\(^2\) This article reports an extremely rare case of MPM, epithelioid subtype, which was complicated by ascites.

Case Presentation
An 88-year-old male was admitted to the medical floor with a 2-week history of abdominal distention and bloating. The patient reported associated decreased appetite, early satiety, and generalized weakness. He was actively working as a part-time barber for the past 55 years. Prior to that, he worked at an insulation production factory between the ages of 23 and 25 years with presumed asbestos exposure. Additional exposure history significant for 10 pack-year smoking (1 pack \(\times\) 10 years) and significant passive smoking exposure. Physical examination was notable for distended abdomen with mild tenderness to deep palpation in all quadrants. There was no rebound tenderness or guarding. Fluid wave test was positive, and he had lower extremity edema. Initial laboratory workup was unremarkable, except for low serum albumin (Table 1). Computed tomography (CT) scan of the abdomen/pelvis with contrast showed diffuse omental, peritoneal, and mesenteric nodularity with moderate to large ascites (Figure 1). Given these new findings, workup was directed to look for the primary malignancy. CT chest with contrast was done, which was negative for primary lung malignancy. However, CT chest with contrast showed bilateral pleural plaques indicating prior asbestos exposure. Esophagogastroduodenoscopy and colonoscopy were unremarkable. Tumor markers CEA, PSA, CA 19-9, and AFP were also within normal limits. Therapeutic and diagnostic paracentesis were done, which yielded 2.5 liters of blood-tinted fluid. Ascitic fluid analysis revealed the values shown in Table 2.

Serum-ascites albumin gradient was calculated at <0.7, indicating ascites not associated with portal hypertension. Given the findings of the fluid analysis and CT abdomen, the patient underwent ultrasound-guided omental biopsy. Tumor cells were positive for calretinin, WT-1, CK5/6, and mesothelia

---

1Southern Illinois University, Springfield, IL, USA
2Johns Hopkins University, Baltimore, MD, USA

Received September 1, 2018. Revised September 10, 2018. Accepted September 23, 2018.

Corresponding Author:
Abdisamad M. Ibrahim, Southern Illinois University School of Medicine, 701 N First Street, Rm D442, Springfield, IL 62702, USA.
Email: qalbinoor@gmail.com
Journal of Investigative Medicine High Impact Case Reports

(Figure 2) confirming the diagnosis of MPM, epithelioid subtype. Given the patient’s advanced age and his medical comorbidities (coronary artery disease and hypertension), the patient was deemed not a candidate for cytoreductive surgery (CRS) or platinum-based chemotherapy. With the poor prognosis of MPM in mind, the patient opted not to pursue further treatment and decided to go home with home hospice. Palliative peritoneal catheter was placed, and the patient was discharged home with home hospice care.

**Discussion**

Mesothelioma is a rare malignant neoplasm that arises from the cell lining of the serosal surfaces. It commonly arises from the pleural serosal surface, more often than the peritoneum. This is the case in 10% to 15% of mesotheliomas, as is in our patient. As the case in other forms of mesotheliomas, the cumulative asbestos exposure remains the leading cause of MPM. Other etiologies include para-exposure, such as laundering the clothes of an exposed person, therapeutic irradiation, chronic inflammatory peritonitis, and simian virus-40.

MPM is a challenging entity. First, diagnosis can be difficult to establish given the nonspecific symptoms at the time of presentation, resulting in delayed diagnosis. The estimated mean time to diagnosis is 122 days. The second challenge, as illustrated before, is that not all patients have a history of asbestos exposure. Therefore, when faced with abdominal pain and/or abdominal distention/ascites, which are the 2 important manifestations of MPM, especially in the history of asbestos exposure, it is essential to seek further imaging. CT scan of the abdomen can help make the diagnosis and usually can show diffuse peritoneal masses invading the omentum, pleural thickening, nodularity, and/or omental caking. Diagnosis should be confirmed through omental biopsy.

The overall prognosis of MPM remains poor, with a median survival time of 12 months at time of diagnosis. Treatment modalities offered in the United States include chemotherapy alone, CRS alone, and CRS/chemotherapy combination. In a recently published study, poor prognostic variables included advanced age, male gender, uninsured/Medicaid insurance, and sarcomatoid/biphasic histology. In addition, combined modality of treatment (CRS/chemotherapy) seems to be associated with the longest median survival, 61 months.

In the index case, the patient had poor prognostic factors, such as male gender and advanced age. He also had multiple medical comorbidities, such as coronary artery disease and hypertension. Given the above-mentioned conditions, risks and benefits of CRS and chemotherapy were put into consideration. Our patient opted not to pursue further treatment and decided to go home with home hospice.

This case report highlights the importance of including MPM in the differential diagnosis of patients presenting with

### Table 1. Laboratory Evaluation.

| Test                      | Value       |
|---------------------------|-------------|
| Hemoglobin                | 14.6 g/dL   |
| Hematocrit                | 44%         |
| White blood cell          | 8.6 K/cumm  |
| Potassium                 | 314 K/cumm  |
| Sodium                    | 136 mmol/L  |
| Potassium                 | 4.5 mmol/L  |
| Blood urea nitrogen       | 14 mg/dL    |
| Creatinine                | 1.2 mg/dL   |
| Alkaline phosphatase      | 50 IU/L     |
| Aspartate aminotransferase| 36 IU/L     |
| Alanine aminotransferase  | 26 IU/L     |
| Albumin                   | 2.9 g/dL    |
| Total protein             | 4.7 g/dL    |

### Table 2. Ascitic Fluid Analysis.

| Test                       | Value       |
|----------------------------|-------------|
| Fluid white blood cells    | 720/cumm    |
| Fluid red blood cells      | 60 075/cumm |
| Fluid neutrophils          | 10%         |
| Fluid lymphocytes          | 64%         |
| Fluid monocytes            | 26%         |
| Fluid macrophages          | Moderate    |
| Fluid mesothelial cells    | Moderate    |
| Fluid glucose              | 73 mg/dL    |
| Fluid pH                   | 7.0         |
| Fluid protein              | 3.4 g/dL    |
| Fluid albumin              | 2.2 g/dL    |

**Figure 1.** Computed tomography scan of the abdomen showing peritoneal nodularity.
new ascites, especially with history of asbestos exposure. It is important to seek further diagnostic imaging including CT scan of the abdomen and biopsy of any suspicious lesions. Unfortunately, the prognosis remains dim in this condition.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics Approval
Our institution does not require ethical approval for reporting individual cases or case series.

Informed Consent
Written informed consent was obtained from the patient for their anonymized information to be published in this article.

ORCID iD
Abdisamad M. Ibrahim https://orcid.org/0000-0001-7496-2198

References
1. Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED. US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. *Eur J Cancer Prev*. 2008;17:525-534.
2. Algin MC, Yaylak F, Bayhan Z, Aslan F, Bayhan NA. Malignant peritoneal mesothelioma: clinicopathological characteristics of two cases. *Case Rep Surg*. 2014;2014:748469. doi:10.1155/2014/748469
3. Frontario SC, Loveitt A, Goldenberg-Sandau A, Liu J, Roy D, Cohen LW. Primary peritoneal mesothelioma resulting in small bowel obstruction: a case report and review of literature. *Am J Case Rep*. 2015;16:496-500. doi:10.12659/AJCR.894180
4. Zha BS, Flanagan M, Coulson C, Garvin KW. Difficult to identify: malignant primary peritoneal mesothelioma. *Am J Med*. 2015;128:1191-1194. doi:10.1016/j.amjmed.2015.06.021
5. Verma V, Sleightholm RL, Rusthoven CG, et al. Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival. *Ann Surg Oncol*. 2018;25:2018-2026. doi:10.1245/s10434-018-6499-1